ArticleJTO clinical and research reports2026
First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report.
Brandon Poppe et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.